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Abstract
Background: Previous efforts to eradicate malaria parasites, particularly Plasmodium falciparum, have failed in part
due to the emergence of drug resistant parasites and mosquitoes resistant to insecticides. Using an artemisinin-
based combination therapy (ACT) that kills parasites quickly, a strategy was designed to eliminate the source of
transmission by mass treatment of human populations in malaria-endemic areas Cambodia.
Methods: A combination drug of artemisinin and piperaquine given with low doses of primaquine was used to
eliminate all stages of parasites from human carriers.
Results: In a pilot study, mass administration of artemisinin-piperaquine (two tablets of 62.5 mg artemisinin and
375 mg piperaquine for adults aged ≥16 years at 0 and 24 hrs; 1.5 tablet for children aged 11-15 years; and one
tablet for children aged 6-10 years) and primaquine (9 mg for adults, at 10 day intervals for 6 months) was carried
out in 17 villages (3,653 individuals). Parasite rates were dramatically reduced from 52.3% to 2.6% after three years.
The P. falciparum rate in children decreased from 37.0% to 1.4%, reaching 0% in eight of 17 villages. In a second
field study, that included one additional mass treatment of artemisinin-piperaquine, the P. falciparum rate in
children was reduced from 20.8% to 0% within six months. No major adverse effects were observed.
Conclusions: Mass administration of artemisinin-piperaquine and low doses of primaquine can be an effective,
safe, and affordable strategy for efficiently eliminating malaria parasites in human carriers and interrupting parasite
transmission. This study provides important information for future strategies for the eradication of malaria.
Background
Malaria has been eliminated from some formerly ende-
m i cr e g i o n so ft h ew o r l d ,m a i n l yi nm o r et e m p e r a t e
zones including countries in Europe, North America,
some of the former Soviet Republics, and some island
nations. Improvement in public health, efforts in treating
malaria patients, and mosquito control measures were
some key factors for the success of malaria elimination.
Unfortunately, malaria control programmes have been
less successful in many developing countries in the tro-
pics and subtropics. Lack of resources for disease man-
agement and the emergence of drug resistant parasites
and insecticide resistant mosquitoes contributed to the
failure of many malaria eradication programmes during
the era of the Global Malaria Eradication Programme
initiated by the World Health Organization in 1955 [1].
Similarly, the goals of the1998 Action Plan to Roll Back
Malaria have not been fulfilled in many countries [2]. In
China, integrated malaria control programmes, such as
mosquito and transmission control, have been in place to
eliminate the disease since the late 1950s [3]. However, it
took over 30 years to control Plasmodium vivax malaria
in endemic areas along the Yangtze River [4]. Although
Plasmodium falciparum malaria has been eliminated in
many endemic regions in China, the parasite is still pre-
sent in Hainan and Yunnan provinces in Southern China
after more than 50 years of disease control efforts [5,6].
To reduce or totally eliminate malaria parasite infec-
tions from a population, interruption of parasite
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any medium, provided the original work is properly cited.transmission is critical. One strategy for achieving the
goal is to interrupt parasite transmission through mos-
quito vector control such as insecticide spraying and
large-scale distribution of insecticide-impregnated bed
nets [7]. Although some successes have been achieved
through these efforts, vector control in most endemic
regions has had limited success at sustained interruption
of transmission, especially when applied in isolation
without aggressive drug treatment and prevention stra-
tegies. A second approach is to eliminate parasites from
the human reservoir with anti-malarial drugs. Unfortu-
nately, many anti-malarial drugs cannot kill sexual
stages in a human host and, therefore, cannot block
parasite transmission even when blood stage parasites
are eliminated and the patient is successfully treated for
malaria symptoms. Additionally, the emergence of para-
sites resistant to anti-malarial drugs has contributed to
resurgence of malaria cases in recent decades [8].
Rapid-acting artemisinin combination therapy (ACT)
provides a potential tool for malaria control and eradica-
tion by removing the source of malaria transmission
through eliminating parasites in the human populations.
This strategy has been shown tob ee f f e c t i v ep r e v i o u s l y ,
particularly when combined with anti-vector methods
[ 9 - 1 1 ] .T h i sa p p r o a c hi sa l s oc o n s i s t e n tw i t hp r e v i o u s
experiences in eliminating malaria parasites from places
with endemic malaria or with malaria outbreaks (personal
communication with Qilin Huang, Institute of Anti-Parasi-
tic Diseases, Guangdong Province, China). Where malaria
rates are low, malaria outbreaks have occurred because of
transmission from undiagnosed and untreated imported
carriers. Indeed, the successful eradication of malaria from
regions such as North America was achieved largely
through eliminating malaria parasites from human popula-
tions, not by eliminating their mosquito vectors.
To investigate the feasibility of eradicating malaria
parasites from endemic regions through eliminating the
sources of host transmission, two pilot studies were con-
ducted in Cambodia during December 2003 to Decem-
ber 2006. Here results are presented from the studies
testing a hypothesis that mass treatment with an ACT
followed by primaquine to block transmission is an
effective method for reducing and/or arresting malaria
transmission in endemic area.
Methods
Study population
T h ep o p u l a t i o nf o rt h ef i r s ts t u d yc o n s i s t e do f3 , 6 5 3
individuals from 17 villages in Kampong Speu province,
Cambodia (Figure 1). The second study population
included 2,387 individuals in nine villages in Kampot
province (Figure 1). The majority of the study popula-
tions were of Khmer ethnic origin. The studies were
approved by Institutional Review Boards of the Ministry
of Health, Cambodia and Guangzhou University of Chi-
nese Medicine, Guangzhou, People’s Republic of China.
Drug administration
Village Malaria Volunteers (VMV) were recruited to dis-
tribute drugs and monitor drug administration. Anti-
malarial drugs were given to every individual simulta-
neously in the villages. A complete two-dose therapy of
artemisinin-piperaquine was given to the whole popula-
tion without obtaining individual infection information.
Adults (≥16) were given two tablets of a co-formulated
artemisinin and piperaquine (artemisinin 62.5 mg and
piperaquine 375 mg/tablet, Artequick®, Guangzhou,
PRC) at 0 and 24 hours. For children aged 6-10 years,
one tablet was given at each dose; and for children aged
11-15 years, one and a half tablets were used. For chil-
dren under 6 years, a complete two-dose artemisinin-
piperaquine Granules (artemisinin 24 mg and pipera-
quine 144 mg/sachet) was administered: two sachets
each dose for children aged 5-6 years; 1.5 sachets for
children aged 3-4 years; and one sachet for children
aged 1-2 years. At the same time, low-dose primaquine
tablet (9 mg) for adults was given at 10-day intervals for
six consecutive months without obtaining individual
G6PD information, to prevent transmission to mosqui-
toes from infected subjects. The first dose of primaquine
was taken with artemisinin-piperaquine. The doses of
primaquine for children were: 3/4 tablet for children
aged 11-15 years; 1/2 tablet for children aged 7-10
years; 1/3 for children aged 3-6 years; and 1/4 for chil-
dren aged 1-2 years.
Because some villages still had low parasite rates after
the first pilot study, a second mass treatment of artemisi-
nin-piperaquine was added in the second study in Kampot.
It was observed that it was critical to have well-trained
VMV who could properly administer the drugs. Some of
the VMV were replaced to improve drug distribution. In
the second study in Kampot, the same procedure was
implemented as in the first one, with one additional mass
treatment of artemisinin-piperaquine 42 days after the
first treatment for villages where the parasite rates
remained ≥ 10%. For villages with a positive rate <10%,
mass treatment was given only once as in the first study.
All febrile patients were treated at no cost with com-
plete two-dose regimens of artemisinin-piperaquine and
one dose of primaquine during the project. No specific
vector control measures by other research or charitable
organization were identified in the study areas.
Monitoring parasitaemia
Parasite rates in the whole population and in children
(aged < 16 years) were the main indices used to monitor
malaria prevalence and treatment effectiveness for the
studies.
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Page 2 of 10After the mass treatment programme was started, per-
iodic surveys monitoring parasite positive rates in vil-
lages with initial parasite rates of ≥ 20% were carried
out every 6 months. Parasite rates in 50 adults and 50
children were determined randomly in every village. In a
village with a population less than 100, the number of
adults and children checked was not less than 70% of
the population. When the population parasite rate in a
village was decreased to zero, all negative blood smears
of that village were rechecked by another senior micro-
scopist, appointed by both Chinese and Cambodian
investigators, to confirm the results. One skilled micro-
scopist was responsible for microscopic examination of
blood smears throughout the study so that errors due to
variation of diagnostic skill would be minimized.
Children parasite positive rates in three of the nine
villages in the second study were surveyed by malaria
microscopy on Days 7, 14, 28, 35, 42, 60, 90, 120, 150,
and 180.
Monitoring severe adverse events
Severe adverse events are passively reported by the
VMV. No active monitoring takes place.
Statistical methods
The chi-square test (SPSS 10.0) was used for compari-
sons of parasite rates with two-tailed significance tested
at P < 0.05.
Results
Survey of initial malaria infection
Human populations were surveyed in 27 villages in
Kampong Speu province for malaria parasites before the
programme was started. Three different malaria species,
Figure 1 Study sites in Cambodia. First site, 17 villages in Kampong Speu province; Second site, 9 villages in Kampot province.
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found in the villages.
Among the 27 villages, 17 villages had parasite rates
≥ 20%, six villages had parasite rates 10-19%, and four
villages had parasite rates 6-9%. The 17 villages with
high parasite rates had 3,653 residents, with parasite
rates among children ranging form 19.1% to 81.0%
(Figure 2A). In adults, the parasite rates were similar to
those of children (p = 0.10, paired t-test) (Figure 2B).
Among the three species, P. falciparum was the most
prevalent (68.7% and 58.1%, in the 17 villages with high
parasite rates and in the 10 villages with low parasite
rates, respectively.); P. vivax was the second most preva-
lent (23.8% and 38.7%) followed by P. malariae (7.5%
and 3.2%). Interestingly, there appeared to be no corre-
lation between parasite rates in adults and children
among the villages. That is, villages having the highest
rates in children were not necessarily those with the
highest parasite rates in adults. Similarly, the ratios of
P. falciparum over P. vivax and P. malariae in children
Figure 2 Parasite rates in children (A) and adults (B) from 17 villages before treatment. Parasite rates in adults of Village 15 were not
obtained.
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village.
Survey of glucose-6-phosphate dehydrogenase (G6PD)
deficiency rate
A total of 252 villagers (only one from every family)
were screened for G6PD deficiency using G-6-PDH Kit
Visual Colour, Trinity biotech. The G6PD deficiency
rate is 17.1% (43/252); male 18.6% and female 13.3%.
Dramatic reduction in parasite rates after mass treatment
Dramatic reductions in parasite rates were observed in
the 17 villages after three years of treatment and moni-
toring (Figures 3 and 4). Total average parasite rates in
the whole population decreased from 52.3% at the
beginning of the study to 2.6% at the end of the study
(Table 1). In children, the parasite rate decreased from
55.8% to 15.7% (71.9% reduction) in the first year, to
5.3% (90.5%) in the second and to 2.8% (95.0%) in the
third year. The P. falciparum rate in children decreased
from 37.0% to 10.8% (a reduction of 70.8%) in the first
year, to 2.3% (93.8% reduction) in second years and to
1.4% (96.2% reduction) by the third year. The combined
P. vivax and P. malariae rate decreased from 18.8% to
4.9% (73.9% reduction) in the first year and to 3.0%
(84.0% reduction) in the second year, and 1.4% (92.6%
reduction) in the third year (Table 1).
Reductions in parasite rates for adults were similar to
those for children (Table 1). Parasite rates changed from
46.5% to 10.7% (77.0% reduction) in the first year, to
6.3% (86.5% reduction) in the second year, to 2.1%
(95.5% reduction) in the third year. The P. falciparum
rate decreased from 34.2% to 1.6% (95.3% reduction)
after three years; the combined P. vivax and P. malariae
rate decreased from 12.3% to 0.5% (95.9%). It should be
noted that the P. falciparum positive rate in children in
eight of 17 villages decreased from an average of 46.5%
to 0% 18 months after the start of the mass administra-
tion programme.
Exceptions in rate reductions
Although the mass treatment worked well in most of
the villages, not all villages had similar reductions in
parasite rates after one year (Figure 4). Village 2, 4, 5, 9,
and 12 still had parasite rates higher than 20% 12
months after the baseline measurements (Figure 4A and
Table 2). Interviews with villagers indicated that the
drugs might not be distributed properly through VMV.
Consequently, some VMV were replaced and a second
treatment with artemisinin-piperaquine was given to
residents in the four villages, which resulted in signifi-
cant reduction in parasite positive rates, with three out
of four (village 2, 4 and 12) having 0% of parasite rate
1.5 years after second treatment (Table 3).
The second mass treatment with artemisinin-pipera-
quine was not implemented in village 9 because of logis-
tical problems. The decrease in the parasite rate in
children was 64.2% (compared to ~93% in other villages)
1.5 years after treatment. This could be mainly due to
the interference from a nearby village (SL), a highly
endemic village in a neighbouring province that was not
included in the programme. The village was only three
kilometres away from village 9 and the parasite rate in
children in the nearby village was 51.2%, 77.3% of which
was P. falciparum (Figure 3B). Therefore, the SL village
could be considered as a control village to compare the
parasite positive rate over the same period.
Reduction in gametocyte rate
Plasmodium falciparum gametocyte rates dropped sig-
nificantly (Figure 3), particularly among children (reduc-
tion from 13.1% to 0.8% after 3 years, Table 4).
Improved parasite rate reduction with a second mass
treatment
To achieve parasite clearance from the population in a
shorter time and reduce the risk that parasite carriers
could spread malaria infection, and to eliminate para-
sites from people who experienced recrudescence after a
single treatment, we conducted a second study with one
additional mass treatment. Nine villages in Kampot
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Figure 3 R e d u c t i o ni np a r a s i t er a t e si nc h i l d r e ni nt h e1 7
villages. P. f, P. falciparum; P. v, P. vivax; P. m, P. malariae; PFG, P.
falciparum gametocyte
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Page 5 of 10Figure 4 Parasite rates in children in the 17 villages 12 (A) and 18 (B) months following start of mass drug administration. Village SL is
3 km from Village 9. The high parasite rate might influence the treatment outcomes of nearby Village 9.
Table 1 Average population parasite carriage rates in the 17 villages
Age group Parasite rates (%)
2003.12 2004.07 2004.12 2005.07 2005.12 2006.6 2006.12
Children 55.8 17.5* 15.7* 7.8* 5.3* 1.9* 2.8*
(N = 679) (N = 777) (N = 813) (N = 877) (N = 704) (N = 791) (N = 844)
Adults 46.5 NA 10.7* 4.9* 6.3* NA 2.1*
(N = 415) (N = 796) (N = 616) (N = 366) (N = 436)
Whole population 52.3 - 13.2* 6.6* 5.6* - 2.6*
(N = 1094) (N = 1609) (N = 1493) (N = 1070) (N = 1280)
* P < 0.01 vs. the data obtained in Dec.2003 (before conducting mass treatment); NA, not done.
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Page 6 of 10region (Figure 1) with parasite rates ranging from 2.0%
to over 50.5% (Figure 5A) were selected. Six months
after initiation of the second round of mass treatment,
parasite rates decreased dramatically (Figure 5B). Signifi-
cantly, three of the nine villages had 0% P. falciparum
positive rates at Days 60, 90, 150, and 180 (Figure 6).
While adverse events were not monitored actively, no
untoward drug reactions were passively reported by
VMVs during the projects.
Discussion
This study demonstrated that mass administration of
artemisinin-piperaquine plus primaquine was a practical
and effective way to quickly reduce malaria parasite
infection in general human populations. The method
involves rapidly eliminating the malaria parasites from
malaria cases and asymptomatic carriers, including both
sexual and asexual stages. This was achieved by mass
treatment of human populations with a rapid-acting
ACT to eliminate against asexual stages and primaquine
to kill sexual and liver stages. Three years after starting
the mass administration scheme, the P. falciparum rate
in children in the 17 villages dropped by 96.2%. More-
over, eight of the 17 villages had parasite rate decreased
from 46.5% on average to 0%. The P. falciparum rates
in four of these eight villages stayed at 0% based on sur-
veys at 18, 24, and 30 months.
The success of the programme depended on well-
trained local health workers and village volunteers. It
was also important to enlist the cooperation of village
leaders and to educate the general population to encou-
rage active participation for the mass treatment to be
successful.
This study supports the idea of administering a second
mass treatment twice at 42 days because it is difficult to
enrol every person in the villages in the first mass treat-
ment, and to eliminate recrudescent infections. An Ano-
pheles mosquito can live up to 3-4 weeks or even longer
in ideal situations [12]; and they can bite and re-infect
previously treated individuals if only one mass treatment
is given. In addition, mass treatment in the dry season
when the mosquito population is lowest should be
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Table 3 Changes in children P. falciparum carriage rates
in village No.2, No.4, No.5 and No.12
Village No. P. falciparum carriage rate of children (%)
2003.12 2004.07 2004.12 2005.07 2005.12
02 53.8 20.0 20.9 0* 0
04 48.3 40.9 29.7 6.7* 0
05 47.2 12.2 21.6 0* 1.9
12 30.9 11.1 26.3 6.0* 0
* P < 0.01 vs the data obtained in Dec.2003 (before conducting mass
treatment)
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Page 7 of 10considered. These measures were in fact carried out in
the second study in which the P. falciparum positive
rate in children dropped from 20.8% to 0-1.2% within
the first 1-5 months and to 0% at the 6th month.
Malaria control by attacking the mosquito vector and
by using bed nets, even if insecticide-impregnated, have
had limited success worldwide over the past 50 years.
So there was a growing realization that effective control
of malaria needs new strategies, including the availability
of better drugs and a detailed understanding of the epi-
demiology of local malaria in endemic area [13]. Mass
drug administration through a state-wide quinine distri-
bution has been used to control malaria in Italy in
1900s [8] with success in reduction in malaria mortality
but failure to significantlyr e d u c et r a n s m i s s i o n .M a s s
drug administration schemes should ideally use more
than one drug, preferably combinations including a
rapid-acting schizonticidal drug, such as an artemisinin,
Table 4 Changes in P. falciparum gametocyte carriage rates in the 17 villages
Age group P. falciparum gametocyte carriage rates (%)
2003.12 2004.12 2005.12 2006.6 2006.12
Children 13.1 3.1* 1.2* 0 0.8
(N = 679) (N = 813) (N = 704) (N = 791) (N = 844)
Adults 10.2 1.4* 1.3* - 0.7
(N = 415) (N = 796) (N = 796) (N = 436)
Entire population 12.0 2.3* 1.2* - 0.8
(N = 1094) (N = 1609) (N = 1070) (N = 1280)
* P < 0.01 vs the data obtained in Dec.2003 (before conducting mass treatment)
Figure 5 Parasite rates in children in the 9 villages before (A) and 6 months after mass treatment (B).
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Page 8 of 10that can also kill parasite quickly to reduce the number
of gametocytes in the blood, as well as a drug such as
primaquine that can kill sexual and liver stages to pre-
vent transmission [11]. The effect of artemisinin on
malaria transmissibility relies on its ability to reduce
markedly the formation of mature, infective gametocytes
[14]. The use of multiple drugs can also reduce the
chances of selecting drug resistant parasites.
The studies showed that malaria control through elim-
ination asexual and sexual parasites in carriers (malaria
patients and asymptomatic persons) through mass
administration of artemisinin, piperaquine, and prima-
quine was effective. Safety monitoring was not per-
formed systematically as would be done in a controlled
clinical trial, but there was no indication of clinically
significant adverse drug reactions. Higher doses of pri-
maquine can cause haemolytic anaemia in individuals
with G6PD deficiency, but the lower doses used in this
programme are thought to be safe, based on extensive
experience in malaria elimination campaigns in past
decades. The cost of this approach is also acceptable
since the prices of artemisinin-piperaquine and prima-
quine are relative low ($2/treatment/person) and pay-
ments for local VMVs is affordable.
Although this three-year mass drug administration
project had dramatically reduced parasite rates to very
low levels, including some villages with no detectable
parasites, residual parasites may act as parasite source of
future outbreaks. Another round of treatment is
believed to eliminate the residual parasites from the vil-
lages. Another potential issue is that parasite carriers in
nearby villages may reintroduce the parasites into
villages that were clear of parasites. This concern can be
resolved if a national wide mass treatment campaign is
conducted. A third concern is that mass treatment may
lead to the emergence of drug resistant parasites. The
mass drug administration programme used three differ-
ent drugs at the same time, which should greatly reduce
the chance of encountering drug resistant parasites.
Conclusions
Mass drug administration with artemisinin-piperaquine
and primaquine can be considered as an alternative
strategy for malaria control, and, in combination with
other anti-malarial measures, may provide a tool for
malaria elimination and eradication.
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